Floatz logo

Ribociclib

Carcinosarcoma

Blueprint Medicines CorporationSmall moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

7 Active assets in the Carcinosarcoma cohort.

Asset / SponsorPhaseRating
Carboplatin
Blueprint Medicines Corporation
Phase 3BB
Ifosfamide
GOG Foundation
Phase 3B
Dkn-01
Leap Therapeutics, Inc.
Phase 2B
Carboplatin
Dana-Farber Cancer Institute
Phase 2CCC
Nivolumab
Instituto do Cancer do Estado de São Paulo
Phase 2CCC

View all 12 →

Same molecule, other indications

Ribociclib is also rated in:

hormone receptor-positive breast cancerDormant
BBB
Indicative ·
73 / 100
View asset →
HR+/HER2- Breast CancerDormant
BB
Indicative ·
70 / 100
View asset →
estrogen-receptor positive breast cancerDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →